Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-05-08, Stock:PFE, The news for the past five days is as follows:
2019-05-01: NEWS1: The top 2 health care names to play for a catch-up: Technician.NEWS2: After Hours Most Active for May 1, 2019 :  GPRO, MRK, ZNGA, FITB, PFE, SQ, FCX, S, IQ, XOM, QCOM, ODP.NEWS3: After Hours Most Active for May 1, 2019 :  GPRO, MRK, ZNGA, FITB, PFE, SQ, FCX, S, IQ, XOM, QCOM, ODP.NEWS4: Dow Movers: PFE, AAPL.NEWS5: Dow Movers: PFE, AAPL.NEWS6: Amgen (AMGN) Q1 Earnings Top, Sales Hurt by Pricing Pressure.NEWS7: Amgen (AMGN) Q1 Earnings Top, Sales Hurt by Pricing Pressure.NEWS8: Health Care Sector Update for 05/01/2019: NBRV, TNDM, HUM, JNJ, PFE, ABT, MRK, AMGN.NEWS9: Health Care Sector Update for 05/01/2019: NBRV, TNDM, HUM, JNJ, PFE, ABT, MRK, AMGN.NEWS10: Amgen (AMGN) Q1 Earnings Top, Sales Hurt by Pricing Pressure.NEWS11: Pfizer Inc (PFE) Q1 2019 Earnings Call Transcript.NEWS12: Pfizer Inc (PFE) Q1 2019 Earnings Call Transcript.NEWS13: Pfizer Inc (PFE) Q1 2019 Earnings Call Transcript.NEWS14: Edited Transcript of PFE earnings conference call or presentation 30-Apr-19 2:00pm GMT.
2019-05-02: NEWS1: After Hours Most Active for May 2, 2019 :  PFE, CHK, XOM, ESV, CSTM, SRE.NEWS2: After Hours Most Active for May 2, 2019 :  PFE, CHK, XOM, ESV, CSTM, SRE.NEWS3: Pfizer Stock Rebounds Under Cloud of Negative Charts.NEWS4: Drugmakers’ lobbying spending at 10-year high as Washington targets soaring prices.NEWS5: Exelixis (EXEL) Earnings & Revenues Beat Estimates in Q1.NEWS6: Exelixis (EXEL) Earnings & Revenues Beat Estimates in Q1.NEWS7: Exelixis (EXEL) Earnings & Revenues Beat Estimates in Q1.NEWS8: Glaxo (GSK) Beats on Q1 Earnings & Sales, Shingrix Impresses.NEWS9: Glaxo (GSK) Beats on Q1 Earnings & Sales, Shingrix Impresses.NEWS10: Pfizer Raised Its Fiscal 2019 EPS Guidance.NEWS11: Health Care Sector Update for 05/02/2019: ABIO, CI, TFX, JNJ, PFE, ABT, MRK, AMGN.NEWS12: Health Care Sector Update for 05/02/2019: ABIO, CI, TFX, JNJ, PFE, ABT, MRK, AMGN.NEWS13: Pfizer Reiterated Its Fiscal 2019 Revenue Guidance.NEWS14: Glaxo (GSK) Beats on Q1 Earnings & Sales, Shingrix Impresses.NEWS15: What Are Analysts Recommending for PFE after Q1 Results?.
2019-05-03: NEWS1: Top Stock Reports for Pfizer, Intel & HCA Healthcare.NEWS2: Top Stock Reports for Pfizer, Intel & HCA Healthcare.NEWS3: Top Stock Reports for Pfizer, Intel & HCA Healthcare.NEWS4: Health Care Sector Update for 05/03/2019: XRAY, AZN, IMGN, JNJ, PFE, ABT, MRK, AMGN.NEWS5: Health Care Sector Update for 05/03/2019: XRAY, AZN, IMGN, JNJ, PFE, ABT, MRK, AMGN.NEWS6: Pharma Stock Roundup: MRK, LLY, PFE Report Q1 Earnings, SNY, ABBV  Drugs Get EU Nod.NEWS7: Pharma Stock Roundup: MRK, LLY, PFE Report Q1 Earnings, SNY, ABBV  Drugs Get EU Nod.NEWS8: Pfizer Reiterated Its Fiscal 2019 Expense Guidance.NEWS9: Dow 30 Stock Roundup: AAPL, PFE, MRK, MCD Earnings Impress.NEWS10: Dow 30 Stock Roundup: AAPL, PFE, MRK, MCD Earnings Impress.NEWS11: Pharma Stock Roundup: MRK, LLY, PFE Report Q1 Earnings, SNY, ABBV  Drugs Get EU Nod.NEWS12: Dow 30 Stock Roundup: AAPL, PFE, MRK, MCD Earnings Impress.
2019-05-06: NEWS1: Exelixis Expands Its Sales.NEWS2: Exelixis Expands Its Sales.NEWS3: Conatus' (CNAT) Earnings, Revenues Miss Estimates in Q1.NEWS4: Conatus' (CNAT) Earnings, Revenues Miss Estimates in Q1.NEWS5: 7 Stocks to Buy From the T. Rowe Price Health Sciences Fund.NEWS6: 7 Stocks to Buy From the T. Rowe Price Health Sciences Fund.NEWS7: How Dow Jones&apos; Pfizer Could Take On New Drugs From 2 Biotech Stocks.NEWS8: Conatus' (CNAT) Earnings, Revenues Miss Estimates in Q1.NEWS9: Pfizer Gets FDA Approval for $225,000 Heart Disease Drug.NEWS10: Alnylam Pharmaceuticals Continues Onpattro Launch With More to Come.NEWS11: Alnylam Pharmaceuticals Continues Onpattro Launch With More to Come.NEWS12: 7 Stocks to Buy From the T. Rowe Price Health Sciences Fund.NEWS13: The Zacks Analyst Blog Highlights: Merck, Pfizer, AbbVie, Sanofi and Glaxo.NEWS14: The Zacks Analyst Blog Highlights: Merck, Pfizer, AbbVie, Sanofi and Glaxo.NEWS15: Pfizer gets U.S. approval for $225,000 a year heart drug.NEWS16: Health Care Sector Update for 05/06/2019: ESPR, AXSM, CANF, JNJ, PFE, ABT, MRK, AMGN.NEWS17: Health Care Sector Update for 05/06/2019: ESPR, AXSM, CANF, JNJ, PFE, ABT, MRK, AMGN.NEWS18: The Zacks Analyst Blog Highlights: Merck, Pfizer, AbbVie, Sanofi and Glaxo.NEWS19: Sanofi (SNY) Ex-Dividend Date Scheduled for May 07, 2019.NEWS20: Sanofi (SNY) Ex-Dividend Date Scheduled for May 07, 2019.NEWS21: The Zacks Analyst Blog Highlights: Pfizer, Intel, HCA Healthcare, Xilinx and Cummins.NEWS22: Pfizer gets U.S. approval for $225,000 a year heart drug.NEWS23: Pfizer gets U.S. approval for $225,000 a year heart drug.NEWS24: U.S. FDA Approves VYNDAQEL® and VYNDAMAX™ for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease.
2019-05-07: NEWS1: What Are Analysts Recommending for PFE and GSK in May?.NEWS2: Comparing the Revenue Growth Trajectories of PFE and GSK.NEWS3: Comparing the Relative Valuations of PFE and GSK.NEWS4: Why the politically fueled health care stock crash may be over for now.NEWS5: What's in the Cards for Nektar (NKTR) This Earnings Season?.NEWS6: What's in the Cards for Nektar (NKTR) This Earnings Season?.NEWS7: Ex-Dividend Reminder: American Electric Power, Bio-Techne and Pfizer.NEWS8: Ex-Dividend Reminder: American Electric Power, Bio-Techne and Pfizer.NEWS9: Health Care Sector Update for 05/07/2019: CPRX, GWPH, MNK, JNJ, PFE, ABT, MRK, AMGN.NEWS10: Health Care Sector Update for 05/07/2019: CPRX, GWPH, MNK, JNJ, PFE, ABT, MRK, AMGN.NEWS11: What's in the Cards for Nektar (NKTR) This Earnings Season?.NEWS12: See what the IHS Markit Score report has to say about Pfizer Inc..NEWS13: European Commission Approves LORVIQUA® (lorlatinib) for Certain Adult Patients with Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer.

Answer: Rise